These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 33817539)

  • 1. Effects of Metreleptin on Patient Outcomes and Quality of Life in Generalized and Partial Lipodystrophy.
    Cook K; Adamski K; Gomes A; Tuttle E; Kalden H; Cochran E; Brown RJ
    J Endocr Soc; 2021 Apr; 5(4):bvab019. PubMed ID: 33817539
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New advances in the treatment of generalized lipodystrophy: role of metreleptin.
    Rodriguez AJ; Mastronardi CA; Paz-Filho GJ
    Ther Clin Risk Manag; 2015; 11():1391-400. PubMed ID: 26396524
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Partial and generalized lipodystrophy: comparison of baseline characteristics and response to metreleptin.
    Diker-Cohen T; Cochran E; Gorden P; Brown RJ
    J Clin Endocrinol Metab; 2015 May; 100(5):1802-10. PubMed ID: 25734254
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metreleptin Treatment in a Boy with Congenital Generalized Lipodystrophy due to Homozygous c.465_468delGACT (p.T156Rfs*8) Mutation in the
    Özalkak Ş; Demiral M; Ünal E; Taş FF; Onay H; Demirbilek H; Özbek MN
    J Clin Res Pediatr Endocrinol; 2023 Aug; 15(3):329-333. PubMed ID: 35735786
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic indications and metabolic effects of metreleptin in patients with lipodystrophy syndromes: Real-life experience from a national reference network.
    Mosbah H; Vantyghem MC; Nobécourt E; Andreelli F; Archambeaud F; Bismuth E; Briet C; Cartigny M; Chevalier B; Donadille B; Daguenel A; Fichet M; Gautier JF; Janmaat S; Jéru I; Legagneur C; Leguier L; Maitre J; Mongeois E; Poitou C; Renard E; Reznik Y; Spiteri A; Travert F; Vergès B; Zammouri J; Vigouroux C; Vatier C
    Diabetes Obes Metab; 2022 Aug; 24(8):1565-1577. PubMed ID: 35445532
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of Leptin Therapy on Survival in Generalized and Partial Lipodystrophy: A Matched Cohort Analysis.
    Cook K; Ali O; Akinci B; Foss de Freitas MC; Montenegro RM; Fernandes VO; Gupta D; Lou KJ; Tuttle E; Oral EA; Brown RJ
    J Clin Endocrinol Metab; 2021 Jul; 106(8):e2953-e2967. PubMed ID: 33822100
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metreleptin and generalized lipodystrophy and evolving therapeutic perspectives.
    Tchang BG; Shukla AP; Aronne LJ
    Expert Opin Biol Ther; 2015 Jul; 15(7):1061-75. PubMed ID: 26063386
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Leptin Decreases Energy Expenditure Despite Increased Thyroid Hormone in Patients With Lipodystrophy.
    Grover A; Quaye E; Brychta RJ; Christensen J; Startzell MS; Meehan CA; Valencia A; Marshall B; Chen KY; Brown RJ
    J Clin Endocrinol Metab; 2021 Sep; 106(10):e4163-e4178. PubMed ID: 33890058
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Facial soft tissue volume decreases during metreleptin treatment in patients with partial and generalized lipodystrophy.
    Miehle K; Stumvoll M; Fasshauer M; Hierl T
    Endocrine; 2017 Nov; 58(2):262-266. PubMed ID: 28993984
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Update on Therapeutic Options in Lipodystrophy.
    Akinci B; Meral R; Oral EA
    Curr Diab Rep; 2018 Oct; 18(12):139. PubMed ID: 30370487
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metreleptin Treatment in Patients with Non-HIV Associated Lipodystrophy.
    Akinci G; Akinci B
    Recent Pat Endocr Metab Immune Drug Discov; 2015; 9(2):74-8. PubMed ID: 26556498
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical effects of long-term metreleptin treatment in patients with lipodystrophy.
    Chan JL; Lutz K; Cochran E; Huang W; Peters Y; Weyer C; Gorden P
    Endocr Pract; 2011; 17(6):922-32. PubMed ID: 22068254
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metreleptin-mediated improvements in insulin sensitivity are independent of food intake in humans with lipodystrophy.
    Brown RJ; Valencia A; Startzell M; Cochran E; Walter PJ; Garraffo HM; Cai H; Gharib AM; Ouwerkerk R; Courville AB; Bernstein S; Brychta RJ; Chen KY; Walter M; Auh S; Gorden P
    J Clin Invest; 2018 Aug; 128(8):3504-3516. PubMed ID: 29723161
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The complicated clinical course in a case of atypical lipodystrophy after development of neutralizing antibody to metreleptin: treatment with setmelanotide.
    Akinci B; Meral R; Rus D; Hench R; Neidert AH; DiPaola F; Westerhoff M; Taylor SI; Oral EA
    Endocrinol Diabetes Metab Case Rep; 2020 Mar; 2020():. PubMed ID: 32213649
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endogenous Leptin Concentrations Poorly Predict Metreleptin Response in Patients With Partial Lipodystrophy.
    Meral R; Malandrino N; Walter M; Neidert AH; Muniyappa R; Oral EA; Brown RJ
    J Clin Endocrinol Metab; 2022 Mar; 107(4):e1739-e1751. PubMed ID: 34677608
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metreleptin replacement treatment improves quality of life and psychological well-being in congenital generalized lipodystrophy.
    Simsir IY; Yurekli BS; Polat I; Saygili F; Akinci B
    Natl Med J India; 2020; 33(5):278-280. PubMed ID: 34213454
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metreleptin Treatment in Three Patients with Generalized Lipodystrophy.
    Musso C; Major ML; Andres E; Simha V
    Clin Med Insights Case Rep; 2016; 9():123-127. PubMed ID: 28096701
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnosis, treatment and management of lipodystrophy: the physician perspective on the patient journey.
    Patni N; Chard C; Araújo-Vilar D; Phillips H; Magee DA; Akinci B
    Orphanet J Rare Dis; 2024 Jul; 19(1):263. PubMed ID: 38992753
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of metreleptin in patients with lipodystrophy with and without baseline concomitant medication use.
    Adamski K; Cook K; Gupta D; Morris E; Tuttle E; Carr E; Cremasco F; Cochran E; Brown RJ
    Curr Med Res Opin; 2021 Nov; 37(11):1881-1889. PubMed ID: 34490811
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment Options for Lipodystrophy in Children.
    Mainieri F; Tagi VM; Chiarelli F
    Front Endocrinol (Lausanne); 2022; 13():879979. PubMed ID: 35600578
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.